实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (4): 541-544.doi: 10.3969/j.issn.1672-5069.2026.04.016

• 自身免疫性肝病 • 上一篇    下一篇

自身免疫性肝炎患者血清miR-148a和细胞因子水平变化及其临床意义探讨*

龚莉, 李佳裕, 薛学锋, 季沈杰, 蒋黎黎   

  1. 226200 江苏省启东市 南通大学附属启东医院/启东市人民医院启东肝癌防治研究所检验科
  • 收稿日期:2025-11-28 出版日期:2026-07-10 发布日期:2026-07-20
  • 通讯作者: 蒋黎黎,E-mail:qdjll_2009@126.com
  • 作者简介:龚莉,女,42岁,大学本科,副主任技师。E-mail:13862990853@163.com
  • 基金资助:
    *江苏省南通市卫生健康委员会科研项目(编号:MS2024107)

Implication of serum miR-148a and cytokine levels in patients with autoimmune hepatitis

Gong Li, Li Jiayu, Xue Xuefeng, et al   

  1. Clinical Laboratory, Liver Cancer Prevention and Research Institute, People's Hospital Affiliated to Nantong University, Qidong 226200, Jiangsu Province, China
  • Received:2025-11-28 Online:2026-07-10 Published:2026-07-20

摘要: 目的 探讨自身免疫性肝炎(AIH)患者血清微小RNA(miR)-148a、白介素(IL)-6、IL-17和肿瘤坏死因子-α(TNF-α)水平变化及其临床意义。方法 2022年3月~2025年2月我院诊治的AIH患者61例(轻度28例,中重度33例),给予泼尼松联合硫唑嘌呤治疗6个月。采用免疫比浊法检测血清免疫球蛋白G(IgG)水平,采用实时荧光定量PCR法检测血清miR-148a水平,采用电化学发光法检测血清IL-6、IL-17和TNF-α水平,应用多因素二元Logistic回归分析影响AIH患者治疗应答的因素。结果 在治疗6个月末,中重度组ALT、AST和IgG水平仍显著高于轻度组(P<0.05);血清miR-148a、IL-6、IL-17和TNF-α水平分别为(2.3±0.4)、(21.2±4.3)pg/mL、(16.0±3.3)pg/mL和(19.3±4.2)pg/mL,均仍显著高于轻度组【分别为(1.9±0.3)、(15.3±3.2)pg/mL、(13.5±2.7)pg/mL和(15.2±3.7)pg/mL,P<0.05】;在治疗6个月末,轻度组20例(71.4%)和中重度组19例(57.6%)获得完全应答(CR); 中重度组不完全应答(NCR)患者血清miR-148a、IL-6、IL-17和TNF-α水平均显著高于轻度组NCR患者(P<0.05); 多因素Logistic回归分析显示,血清miR-148a(OR=1.439,95%CI:1.160~1.785)、IL-6(OR=1.701,95%CI:1.323~2.186)、IL-17(OR=1.516,95%CI:1.191~1.929)和TNF-α(OR=1.640,95%CI:1.330~2.023)均是AIH患者治疗不完全应答的独立危险因素(P<0.05)。结论 血清miR-148a及IL-6、IL-17和TNF-α水平可能与AIH患者病情程度密切相关,并可能影响对免疫抑制剂治疗的应答,临床是否可据此优化治疗策略还需要进一步探讨。

关键词: 自身免疫性肝炎, 泼尼松, 微小RNA-148a, 白细胞介素-6, 白细胞介素-17, 肿瘤坏死因子-α, 治疗

Abstract: Objective The aim of this study was to investigate the clinical implication of serum microRNA (miR)-148a, and interleukin (IL)-6, IL-17 and tumor necrosis factor-α (TNF-α) levels in patients with autoimmune hepatitis (AIH). Methods 61 patients with AIH, including mild degree in 28 cases and moderate-to-severe degree in 33 cases, were enrolled in our hospital between March 2022 and February 2025, and all received immunosuppressive therapy for six months. Serum immunoglobulin G (IgG) level was measured by immunoturbidimetry, serum miR-148a load was detected by real-time fluorescence quantitative PCR, and serum IL-6, IL-17 and TNF-α levels were detected by magnetic particle luminescence method. Multivariate binary Logistic regression was applied to analyze the factors affecting poor or non-complete response (NCR) to immunosuppressive therapy in patients with AIH. Results By the end of 6 months of treatment, serum ALT, AST and IgG levels in patients with moderate-to-severe degree were all much higher than in those with mild degree (P<0.05); serum miR-148a, IL-6, IL-17 and TNF-α levels in patients with moderate-to-severe degree were (2.3±0.4), (21.2±4.3)pg/mL, (16.0±3.3)pg/mL and (19.3±4.2)pg/mL, all significantly higher than [(1.9±0.3), (15.3±3.2)pg/mL, (13.5±2.7)pg/mL and (15.2±3.7)pg/mL, respectively, P<0.05] in those with mild degree; at end of 6 month treatment, 20 patients (71.4%) in mild group and 19 patients (57.6%) in moderate-to-severe degree obtained complete response (CR); serum miR-148a, IL-6, IL-17 and TNF-α levels in NCR patients in moderate-to-severe degree group were still much higher than in NCR patients in mild group (P<0.05); multivariate Logistic regression analysis showed that serum miR-148a(OR=1.439, 95%CI:1.160-1.785), IL-6(OR=1.701,95%CI:1.323-2.186), IL-17(OR=1.516,95%CI:1.191-1.929) and TNF-α(OR=1.640,95%CI:1.330-2.023) were all the independent risk factors for NCR in patients with AIH(P<0.05). Conclusion Serum miR-148a, IL-6, IL-17 and TNF-α are closely related to the disease severity in patients with AIH, which might impact response to immunosuppressive therapy, and needs further investigation.

Key words: Autoimmune hepatitis, Prednisone, MicroRNA-148a, Interleukin-6, Interleukin-17, Tumor necrosis factor-α, Therapy